Cost comparison of gastrojejunostomy versus duodenal stent placement for malignant gastric outlet obstruction

J Gastroenterol. 2010 May;45(5):537-43. doi: 10.1007/s00535-009-0181-0. Epub 2009 Dec 22.

Abstract

Background: Gastrojejunostomy (GJJ) and stent placement are the most commonly used palliative treatments for malignant gastric outlet obstruction (GOO). In a recent randomized trial, stent placement was preferred in patients with a relatively short survival and GJJ in patients with a longer survival. As health economic aspects have only been studied in general terms, we estimated the cost of GJJ and that of stent placement in such patients.

Methods: In the SUSTENT study, patients were randomized to GJJ (n = 18) or stent placement (n = 21). Pancreatic cancer was the most common cause of GOO. We compared initial costs and costs during follow-up. For cost-effectiveness, the incremental cost-effectiveness ratio was calculated.

Results: Food intake improved more rapidly after stent placement than after GJJ, but long-term relief of obstructive symptoms was better after GJJ. More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ. Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001). We found no difference in follow-up costs. Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049). The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.

Conclusions: Medical effects were better after GJJ, although GJJ had higher total costs. Since the cost difference between the two treatments was only small, cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO (ISRCTN 06702358).

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Cost-Benefit Analysis
  • Digestive System Neoplasms / complications
  • Digestive System Neoplasms / pathology
  • Digestive System Neoplasms / therapy
  • Duodenoscopy / economics*
  • Duodenum
  • Female
  • Gastric Bypass / economics*
  • Gastric Outlet Obstruction / economics
  • Gastric Outlet Obstruction / etiology
  • Gastric Outlet Obstruction / surgery*
  • Health Care Costs*
  • Humans
  • Male
  • Middle Aged
  • Palliative Care / economics*
  • Quality of Life
  • Recurrence
  • Stents / economics*
  • Treatment Outcome

Associated data

  • ISRCTN/ISRCTN06702358